Big Pharma Split Corp Class A Cash Flow Conversion Efficiency
Big Pharma Split Corp Class A cash flow conversion efficiency. Based on the latest financial reports, Big Pharma Split Corp Class A (PRM) has a cash flow conversion efficiency ratio of -0.053x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-1.04 Million ≈ $-750.25K USD) by net assets (CA$19.44 Million ≈ $14.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Big Pharma Split Corp Class A (2017–2025)
Cash flow conversion efficiency of Big Pharma Split Corp Class A from 2017 to 2025. This chart illustrates how Big Pharma Split Corp Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Big Pharma Split Corp Class A stock price today for real-time trading data and today's change.
Big Pharma Split Corp Class A Cash Flow Conversion Ratio Explained
Big Pharma Split Corp Class A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Big Pharma Split Corp Class A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Big Pharma Split Corp Class A ranked by their cash flow conversion efficiency. Also see Big Pharma Split Corp Class A stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Brag House Holdings, Inc. Common Stock
NASDAQ:TBH
|
-0.701x |
|
Scan Inter PCL
BK:SCN
|
0.030x |
|
PROBIOTIX HEALTH LS-05
F:X90
|
N/A |
|
High Peak Royalties Ltd
AU:HPR
|
-0.016x |
|
Moorim SP Co. Ltd
KQ:001810
|
-0.006x |
|
Close the Loop Ltd
AU:CLG
|
0.019x |
|
Havsfrun Investment AB (publ)
ST:HAV-B
|
-0.012x |
|
Nexgram Holdings Bhd
KLSE:0096
|
-0.009x |
Annual Cash Flow Conversion Efficiency for Big Pharma Split Corp Class A (2017–2025)
The table below shows the annual cash flow conversion efficiency of Big Pharma Split Corp Class A from 2017 to 2025. Review PRM free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$18.27 Million ≈ $13.21 Million |
CA$-1.06 Million ≈ $-763.18K |
-0.058x | +39.01% |
| 2024-12-31 | CA$13.68 Million ≈ $9.90 Million |
CA$-1.30 Million ≈ $-937.16K |
-0.095x | -112.66% |
| 2023-12-31 | CA$15.85 Million ≈ $11.47 Million |
CA$11.86 Million ≈ $8.58 Million |
0.748x | +1208.10% |
| 2022-12-31 | CA$19.73 Million ≈ $14.27 Million |
CA$1.13 Million ≈ $816.29K |
0.057x | +114.24% |
| 2021-12-31 | CA$22.40 Million ≈ $16.21 Million |
CA$-9.00 Million ≈ $-6.51 Million |
-0.402x | -221.81% |
| 2020-12-31 | CA$13.19 Million ≈ $9.54 Million |
CA$4.35 Million ≈ $3.15 Million |
0.330x | -38.03% |
| 2019-12-31 | CA$16.31 Million ≈ $11.80 Million |
CA$8.68 Million ≈ $6.28 Million |
0.532x | +689.14% |
| 2018-12-31 | CA$18.84 Million ≈ $13.63 Million |
CA$1.27 Million ≈ $919.19K |
0.067x | +104.07% |
| 2017-12-31 | CA$18.68 Million ≈ $13.51 Million |
CA$-30.95 Million ≈ $-22.39 Million |
-1.657x | -- |
About Big Pharma Split Corp Class A
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada.